Učitavanje...
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
A pharmacokinetics (PK)/pharmacodynamics (PD) study (EudraCT number 2015‐002966‐21) was conducted to investigate the biosimilarity of Pelmeg(®) (pegfilgrastim), a biosimilar to EU‐authorized Neulasta(®), which is used in the clinic for prevention of chemotherapy‐induced neutropenia. The single‐dose,...
Spremljeno u:
| Izdano u: | Pharmacol Res Perspect |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6691757/ https://ncbi.nlm.nih.gov/pubmed/31417680 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.503 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|